Abstract:A successful treatment of AIDS world-wide is severely hindered by the HIV virus' drug resistance capability resulting from complicated mutation patterns of viral proteins. Such a system of mutations enables the virus to survive and reproduce despite the presence of various antiretroviral drugs by disrupting their binding capability. Although these interacting mutation patterns are extremely difficult to efficiently uncover and interpret, they contribute valuable information to personalized therapeutic regimen design. The use of Bayesian statistical modeling provides an unprecedented opportunity in the field of anti-HIV therapy to understand detailed interaction structures of drug resistant mutations. Multiple Bayesian models equipped with Markov Chain Monte Carlo (MCMC) methods have been recently proposed in this field (Zhang et al. in PNAS 107: 1321, 2010 [1]; Zhang et al. in J Proteome Sci Comput Biol 1: 2, 2012 [2]; Svicher et al. in Antiviral Res 93(1): 86-93, 2012 [3]; Svicher et al. in Antiviral Therapy 16(7): 1035-1045, 2011 [4]; Svicher et al. in Antiviral Ther 16(4): A14-A14, 2011 [5]; Svicher et al. in Antiviral Ther 16(4): A85-A85, 2011 [6]; Alteri et al. in Signature mutations in V3 and bridging sheet domain of HIV-1 gp120 HIV-1 are specifically associated with dual tropism and modulate the interaction with CCR5 N-Terminus, 2011 [7]). Probabilistically modeling mutations in the HIV-1 protease or reverse transcriptase (RT) isolated from drug-treated patients provides a powerful statistical procedure that first detects mutation combinations associated with single or multiple-drug resistance, and then infers detailed dependence structures among the interacting mutations in viral proteins (Zhang et al. in PNAS 107: 1321, 2010 [1]; Zhang et al. in J Proteome Sci Comput Biol 1: 2, 2012 [2]). Combined with molecular dynamics simulations and free energy calculations, Bayesian analysis predictions help to uncover genetic and structural mechanisms in the HIV treatment resistance. Results obtained with such stochastic methods pave the way not only for optimization of the use for existing HIV drugs, but also for the development of the new more efficient antiretroviral medicines. In this chapter we survey current challenges in the bioinformatics of anti-HIV therapy, and outline how recently emerged Bayesian methods can help with the clinical management of HIV-1 infection. We will provide a rigorous review of the Bayesian variable partition model and the recursive model selection procedure based on probability theory and mathematical data analysis techniques while highlighting real applications in HIV and HBV studies including HIV drug resistance (Zhang et al. in PNAS 107: 1321, 2010 [1]), cross-resistance (Zhang et al. in J Proteome Sci Comput Biol 1: 2, 2012 [2]), HIV coreceptor usage (Svicher et al. in Antiviral Therapy 16(7): 1035-1045, 2011 [4]; Svicher et al. in Antiviral Ther 16(4): A14-A14, 2011 [5]; Alteri et al. in Signature mutations in V3 and bridging sheet domain of HIV-1 gp120 HIV-1 are specifically associated with dual tropism and modulate the interaction with CCR5 N-Terminus, 2011 [7]), and occult HBV infection (Svicher et al. in Antiviral Res 93(1): 86-93, 2012 [3]; Svicher et al. in Antiviral Ther 16(4): A85-A85, 2011 [6]).

Dynamics Behavior of Mutation During Reproduction on Hiv-1 Drug Resistance

Mathematical Analysis of the Probability of Spontaneous Mutations in HIV-1 Genome and Their Role in the Emergence of Resistance to Anti-Retroviral Therapy

Global dynamics for a drug-sensitive and drug-resistant mixed strains of HIV infection model with saturated incidence and distributed delays

Mathematical analysis of an HIV model with latent reservoir, delayed CTL immune response and immune impairment

Mathematical modelling of the within-host HIV quasispecies dynamics in response to antiviral treatment

A mathematical model for HIV dynamics with multiple infections: implications for immune escape

Mathematical modeling of escape of HIV from cytotoxic T lymphocyte responses

Detecting and Understanding Combinatorial Mutation Patterns Responsible for HIV Drug Resistance

Analysis of a Stochastic Predator-Prey Model with Applications to Intrahost HIV Genetic Diversity

Bayesian analysis of complex interacting mutations in HIV drug resistance and cross-resistance.

An in-host model of HIV incorporating latent infection and viral mutation

On the Dynamics of the Evolution of the HIV Infection

Evolving Mutational Buildup in HIV-1 Protease Shifts Conformational Dynamics to Gain Drug Resistance

A model of HIV drug resistance driven by heterogeneities in host immunity and adherence patterns

Simulating Genomes and Populations in the Mutation Space: An example with the evolution of HIV drug resistance

Stability analysis for a HIV model with cell-to-cell transmission, two immune responses and induced apoptosis

HIV exposure category and invasive cervical carcinoma in Italy.

Role of ART and PrEP treatments in a stochastic HIV/AIDS epidemic model

The transmission of drug-resistant strains of HIV in heterosexual populations based on genetic sequences

Mathematical Model of HIV superinfection dynamics and R5 to X4 switch

Continuous and discrete dynamics of a deterministic model of HIV infection